cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Century Therapeutics Inc
2 own
1 watching
Current Price
$1.42
$0.05
(3.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
175.83M
52-Week High
52-Week High
10.95000
52-Week Low
52-Week Low
1.28000
Average Volume
Average Volume
0.1M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization175.83M
icon52-Week High10.95000
icon52-Week Low1.28000
iconAverage Volume0.1M
iconDividend Yield--
iconP/E Ratio--
What does the Century Therapeutics Inc do?
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company s lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Read More
How much money does Century Therapeutics Inc make?
News & Events about Century Therapeutics Inc.
Benzinga
7 months ago
Latest Ratings for IPSC DateFirmActionFromTo Nov 2021SVB LeerinkMaintainsOutperform Jul 2021B of A SecuritiesInitiates Coverage OnBuy Jul 2021SVB LeerinkInitiates Coverage OnOutperform View More Analyst Ratings for IPSC View the Latest Analyst Ratings read more...
Globe Newswire
7 months ago
Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer Michael C. Diem, M.D., promoted to Chief Financial Officer Hy Levitsky, M.D., rejoins as President of ...
Zolmax
8 months ago
Century Therapeutics, Inc. (NASDAQ:IPSC Get Rating) insider Luis Borges sold 63,616 shares of the firms stock in a transaction dated Tuesday, March 21st. The shares were sold at an average price of $3.77, for a total transaction of $239,832.32. Following the completion of the transaction, the ...
Ticker Report
8 months ago
Century Therapeutics, Inc. (NASDAQ:IPSC Get Rating) insider Luis Borges sold 63,616 shares of the firms stock in a transaction dated Tuesday, March 21st. The shares were sold at an average price of $3.77, for a total transaction of $239,832.32. Following the completion of the ...
Globe Newswire
8 months ago
- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway - - Ended 2022 with cash, cash equivalents, and investments of $367.4 million; Cash runway expected into 2026 PHILADELPHIA, March 16, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC...
Frequently Asked Questions
Frequently Asked Questions
What is Century Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Century Therapeutics Inc shares?
plus_minus_icon
How can I buy Century Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Century Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Century Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Century Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Century Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Century Therapeutics Inc?
plus_minus_icon
What percentage is Century Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Century Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.42
$0.05
(3.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00